Successful tyrosine kinase inhibitor discontinuation outside clinical trials — data from the population‐based Swedish chronic myeloid leukaemia registryHjalmar Flygt, Johan Richter, Stina Söderlund et al.|British Journal of Haematology|2021Cited by 15
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trialHjalmar Flygt, Ulla Olsson‐Strömberg, Stina Söderlund et al.|Leukemia|2024Cited by 13
Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 studyHjalmar Flygt, Henrik Hjorth‐Hansen, Stina Söderlund et al.|European Journal Of Haematology|2021Cited by 10
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trialHjalmar Flygt, Ulla Olsson‐Strömberg, Stina Söderlund et al.|Research Square|2023Cited by 2
Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trialHjalmar Flygt, Ulla Olsson‐Strömberg, Stina Söderlund et al.|Leukemia|2024Cited by 0